Kuros Biosurgery Granted Patent for Bone Generation Drug/Biologic

Kuros Biosurgery was granted European Patent No 2686027, Pharmaceutical Formulation for Use in Spinal Fusion. This patent claims certain matrix materials in combination with parathyroid hormone (PTH) or derivatives of PTH.

The patent strengthens the intellectual property around Fibrin-PTH, Kuros’s drug/biologic combination product for bone generation. Fibrin-PTH (also known as KUR-113) recently entered a U.S. Phase II STRUCTURE clinical study in spinal fusion.

Joost de Bruijn, Chief Executive Officer, said, “Adding this patent to our broad intellectual property portfolio further reinforces Kuros’s position as a leader in the field of orthobiologics. We look forward to bringing our Fibrin-PTH product candidate (KUR-113) to market and to expanding the number of patients benefiting from our products.”